Skip to content

LACTACOL 01 - Impact of Breast Milk on the Neurodevelopment of Preterm Newborns

BRD/11/02-Y LACTACOL 01 - Impact of Breast Milk on the Neurodevelopment of Preterm Newborns.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01493063
Enrollment
160
Registered
2011-12-15
Start date
2011-10-25
Completion date
2025-09-30
Last updated
2023-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prematurity of Fetus

Keywords

preterm infant

Brief summary

The aim of the study is to estimate the impact of the protein content of breastmilk at the end of hospitalization of the preterm newborn, on the neurodevelopment at 2 years old. The investigators expect a difference of at least 5 points of Development Quotient (DQ) when comparing extreme terciles of the protein content of breastmilk at the end of hospitalization.

Interventions

Samples of breastmilk and infant serum and questionnaires.

Sponsors

Nantes University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
28 Weeks to 34 Weeks
Healthy volunteers
No

Inclusion criteria

* Maternal decision of breastfeeding * Born between 28 and 34 weeks of amenorrhea * No important congenital pathology except prematurity * Efficiency of the breastfeeding compatible with the research by the investigator * Information and authorization of the parents or the parental authority

Exclusion criteria

* Maternal decision of not breastfeeding * Born before 28 weeks of amenorrhoea or after or at 34 weeks of amenorrhoea * Important congenital pathology * Efficiency of the breastfeeding incompatible with the research by the investigator * Opposition from parents or the parental authority to participate to the research study

Design outcomes

Primary

MeasureTime frameDescription
To assess the impact of the protein content of human milk on the neuro-motor development of the preterm infant at 2 years of ageAt 2 years of ageASQ (Ages and Stages Questionnaires) score at 2 years of age. The calculation of the sample size is only based on this endpoint. We wish to highlight a difference of at least 25 points of the ASQ score between both extreme terciles of protein concentration determined in breast milk at the end of hospitalization, when breastfeeding is exclusive (last sample of breastmilk before the end of hospitalization).

Secondary

MeasureTime frameDescription
To assess the impact of the protein content of human milk on the physical activity of the preterm infantAt 7-8 years of ageActimeter (ACTIGRAPH®)
To assess the impact of the protein content of human milk on feeding behaviorAt 2 years of age and at 7-8 years of ageDietary behavior
To assess the impact of the protein content of human milk on growth trajectory and metabolic status of the preterm infantAt 2 years of age and at 7-8 years of ageStaturo-weight growth rate
To assess the impact of the protein content of human milk on the coginitive intelligence of the preterm infantAt 7-8 years of ageStandardized and validated test WISC V
To assess the impact of the protein content of human milk on the executive functioning of the preterm infantAt 7-8 years of ageStandardized and validated test FEE
To assess the impact of the protein content of human milk on the executive dysfunction of the preterm infantAt 7-8 years of ageStandardized and validated test BRIEF battery
To assess the impact of the protein content of human milk on the child's behaviour in the classroom of the preterm infantAt 7-8 years of ageStandardized and validated test GSA
To assess the impact of the protein content of human milk on the generalist clinical evaluation of the preterm infantAt 7-8 years of ageStandardized and validated test BMT-i
To assess the impact of the protein content of human milk on the Body composition (% fat/lean mass)At 2 years of age and at 7-8 years of ageBody composition (% fat/lean mass)

Other

MeasureTime frameDescription
Ancillary study 2.To assess the chemical safety of human milk:identification of nutritional and environmental factors that could explain the presence of chemical contaminantsLevel of chemical contamination of the human milk
Ancillary study N°3. Composition of breast milk and preterm infant's metabolic status and growth trajectory during the first weeks of life. Biomarkers identified in breastmilk and infant serum: lipidome, metabolome, miRNome, amino acids, oligosaccharidesCorrelation obtained between nutritional data from breast milk and identified metabolic markers in children.
Ancillary study N°4. Relationship between breast milk nutritional data and clinical data of mother-child dyads.Correlation obtained between the data.
Ancillary study N°5. Correlation between breast milk protein concentration and neurological development at 7-8 years of age.At 7-8 years of ageCorrelation between breast milk protein concentration and neurological development at 7-8 years of age.
Ancillary study N°6. Equation for estimating fat mass (percentage) in children with the new version of the Biody Xpert device from Aminogram.Validation of an equation for estimating fat mass (percentage) in children with the new version of the Biody Xpert device from Aminogram, using a BodPod measurement as reference.
Ancillary study N°7. Equation for estimating lean mass (percentage) in children with the new version of the Biody Xpert device from Aminogram.Validation of an equation for estimating lean mass (percentage) in children with the new version of the Biody Xpert device from Aminogram, using a BodPod measurement as reference.
Ancillary study 1.To assess the association between maternal eating habits(food intake during lactation estimated using the Food Frequency Questionnaire from the National French birth cohort ELFE), and the nutritional composition of human milk.Association criterion between nutritional composition of human milk assessed by content determination of macro- and micronutrients, and omics approaches (metabolomics,…) and FFQ score

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026